Life-threatening myositis after one dose of nivolumab in a patient with nonmetastatic completely resected cutaneous melanoma

Acta Neurol Belg. 2022 Dec;122(6):1637-1639. doi: 10.1007/s13760-021-01760-9. Epub 2021 Jul 30.

Authors

Tomaž Rus¹, Milica Gregorič Kramberger¹, Gregor Brecl Jakob¹, Lea Leonardis², Marija Meznaric³

Affiliations

¹ Department of Neurology, University Medical Centre Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia.
² Clinical Institute of Clinical Neurophysiology, University Medical Centre Ljubljana, Zaloška cesta 7, 1000, Ljubljana, Slovenia.
³ Faculty of Medicine, Institute of Anatomy, University of Ljubljana, Korytkova 2, 1000, Ljubljana, Slovenia. marija.meznaric@mf.uni-lj.si.

PMID: 34331257
DOI: 10.1007/s13760-021-01760-9

No abstract available

Keywords: Adjuvant therapy; Adverse events; Immune checkpoint inhibitors; Nivolumab-induced myositis; Nonmetastatic melanoma.

Publication types

Letter

MeSH terms

Humans
Melanoma* / drug therapy
Melanoma* / surgery
Melanoma, Cutaneous Malignant
Myositis* / chemically induced
Myositis* / diagnostic imaging
Nivolumab / adverse effects
Skin Neoplasms* / drug therapy
Skin Neoplasms* / surgery

Substances

Nivolumab